Earlier this month, Nektar Therapeutics (NASDAQ: NKTR) told investors it was preparing for the potential launch of a nonaddictive opioid pain reliever that's currently under review. More recently, Nektar shifted gears and decided to spin off its potential new painkiller into a separate company and investors want to know why.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,